t
Sareum Holdings PLC will announce its unaudited half-year results for the six months ended 31 December 2024 on Tuesday, 25 March 2025. On the same day, 25 March 2025, at 14:00 GMT, the Company will hold a live presentation to investors via the Investor Meet Company platform.
| Date | 20 Mar 2025 |
| Time | 07:00:12 |
| Category | Results |
| ID | 3731B |
Sareum Holdings PLC
("Sareum" or the "Company")
Notice of Half-Year Results and Investor Presentation
Cambridge, UK, 20 March 2025 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited half-year results for the six months ended 31 December 2024 on Tuesday, 25 March 2025.
On the same day at 14:00 GMT, the Company will be holding a live presentation to investors via the Investor Meet Company platform.
The presentation is open to all existing and potential shareholders. Questions can be submitted before the event via the Investor Meet Company dashboard up until 25 March 2025, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.
A copy of the presentation will be made available on the Company's website following the presentation.
- ENDS-
For further information, please contact:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Oberon Capital (Joint Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
Hybridan LLP (Joint Broker) Claire Noyce
|
020 3764 2341 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, and is planned to enter clinical development with an initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com